SMMT Q4 2021 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$251,000+35.7% YoY

Gross Profit

$251,000100.0% margin

Operating Income

-$26M-10377.3% margin

Net Income

-$26M-10253.0% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-80.8%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$113M

Total Liabilities

$30M

Stockholders' Equity

$83M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$251,000	$185,000	+35.7%
Gross Profit	$251,000	$185,000	+35.7%
Operating Income	-$26M	-$14M	-92.2%
Net Income	-$26M	-$14M	-89.1%

Revenue Segments

License and Service

$251,000100%

Geographic Segments

Latin America

$251,000100%